HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Traumatic hyphema in children. Treatment with epsilon-aminocaproic acid.

Abstract
Forty-nine patients, ages 3 to 18 years, who sustained nonpenetrating unilateral trauma with hyphemas were assigned randomly to receive either 100 mg/kg of epsilon-aminocaproic acid (EACA), an antifibrinolytic agent, orally every 4 hours for 5 days (maximum 30 g/day) or a placebo. No patients ingested acetylsalicylic acid (ASA)-containing compounds before or during admission. Two patients of 24 treated with EACA and 1 of 25 given placebo had rebleeds. The hyphemas in the EACA-treated group took significantly longer to clear (mean, 5.3 versus 2.6 days; P less than 0.001). Because of the low incidence of rebleeds in the placebo group, the efficacy of EACA in reducing the rate of rebleeds could not be determined. Further studies with this drug, controlling for age, race, sickle trait, and pre-admission antiplatelet agents should be undertaken before its routine use in traumatic hyphema management can be recommended.
AuthorsS P Kraft, M D Christianson, J S Crawford, R D Wagman, J H Antoszyk
JournalOphthalmology (Ophthalmology) Vol. 94 Issue 10 Pg. 1232-7 (Oct 1987) ISSN: 0161-6420 [Print] United States
PMID3317180 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Aminocaproates
  • Aminocaproic Acid
Topics
  • Adolescent
  • Adult
  • Aminocaproates (therapeutic use)
  • Aminocaproic Acid (therapeutic use)
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Double-Blind Method
  • Eye Injuries (complications)
  • Female
  • Follow-Up Studies
  • Humans
  • Hyphema (drug therapy)
  • Male
  • Random Allocation
  • Recurrence

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: